NSPR · InspireMD, Inc.
$0.70
-0.01 (-1.41%)
At close · Jul 17
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has an accumulated deficit as of March 31, 2026, as well as a history of net losses and negative operating cash flows. The Company expects to continue incurring losses and negative cash flows from operations until the Company expands its commercial revenue to a scale that funds its commercial resources, development activities and support functions. As a result of these expected losses and negative cash flows from operations, along with the Company's current cash position, the Company does not have sufficient resources to fund operations for at least the next 12 months. Therefore, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$32.86M
Shares
46.84M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$8.98M
+28.1%
FY2025
Net Income
-$48.79M
-52.4%
FY2025
Gross Margin
29.5%
+8pp
FY2025
Operating Margin
-552.56%
-74.6pp
FY2025
Diluted EPS
-$0.76
0%
FY2025
Operating Cash Flow
-$35.1M
-60.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.85M | $8.98M | $7.01M | $6.21M | $5.17M | $4.5M | $2.49M | $3.72M | $3.6M | $2.76M | $1.89M | $2.31M | $2.82M | $4.87M | $6M | $4.95M | $3.41M | |
| $7.8M | $6.33M | $5.5M | $4.4M | $4.05M | $3.74M | $2.4M | $2.97M | $2.61M | $2.18M | $1.79M | $2.61M | $2.03M | $2.28M | $3.01M | $2.7M | $2.29M | |
| $3.04M | $2.65M | $1.51M | $1.81M | $1.12M | $754K | $83K | $756K | $995K | $585K | $102K | -$296K | $784K | $2.59M | $2.99M | $2.25M | $1.12M | |
| — | 29.5% | 21.49% | 29.12% | 21.6% | 16.77% | 3.34% | 20.32% | 27.63% | 21.19% | 5.39% | -12.81% | 27.82% | 53.15% | 49.85% | 45.52% | 32.83% | |
| $15.71M | $15M | $13.63M | $7.98M | $7.81M | $5.16M | $2.23M | $2.95M | $1.54M | $1.28M | $1.29M | $3.64M | $8.74M | $4.16M | $2.47M | $1.34M | $1.33M | |
| $18.98M | $16.55M | $6.07M | $3.87M | $3.66M | $2.91M | $2.1M | $2.4M | $2.24M | $2.36M | $1.46M | $3.18M | $6.61M | $3.62M | $1.97M | $1.24M | $1.04M | |
| $20.49M | $20.71M | $15.31M | $11.1M | $8.36M | $7.41M | $6.13M | $5.22M | $4.83M | $5.18M | $5M | $6.39M | $9.13M | $8.97M | $12.28M | $2.9M | $1.47M | |
| — | — | — | — | — | — | — | — | — | — | — | — | $148K | $132K | — | — | — | |
| — | $476M | $280M | $232M | $188M | $161K | $151K | $158K | $139K | $153K | $142K | $152K | $263K | $208K | $89K | $91K | $89K | |
| — | — | — | — | — | — | — | — | — | — | — | $406K | — | — | — | — | — | |
| $55.18M | $52.26M | $35.01M | $22.95M | $19.83M | $15.47M | $10.46M | $10.57M | $8.61M | $8.82M | $7.75M | $14.19M | $24.48M | $17.66M | $16.72M | $5.47M | $3.84M | |
| -$52.13M | -$49.61M | -$33.5M | -$21.14M | -$18.71M | -$14.72M | -$10.38M | -$9.82M | -$7.61M | -$8.23M | -$7.65M | -$14.49M | -$23.7M | -$15.07M | -$13.73M | -$3.22M | -$2.72M | |
| — | -552.56% | -478% | -340.74% | -361.88% | -327.39% | -417.71% | -263.8% | -211.36% | -298.15% | -403.8% | -627.06% | -840.95% | -309.32% | -228.66% | -65.04% | -79.65% | |
| — | $426.39M | $246.5M | $210.86M | $169.29M | -$14.56M | -$10.23M | -$9.66M | -$7.47M | -$8.08M | -$7.51M | -$14.33M | -$23.44M | -$14.87M | -$13.64M | -$3.13M | -$2.63M | |
| — | — | — | — | — | — | — | — | — | $119K | $721K | $1.04M | $1.41M | $4.27M | $730K | $105K | $221K | |
| — | — | — | — | — | — | — | — | — | — | — | — | $2000 | $28K | $36K | $1000 | $1000 | |
| $886K | $891K | $1.56M | $1.29M | $250K | -$157K | -$160K | -$200K | -$371K | — | — | — | -$1.39M | -$14.18M | -$934K | -$154K | $40K | |
| — | -$48.72M | -$31.95M | -$19.85M | -$18.46M | -$14.87M | -$10.54M | -$10.02M | -$7.24M | -$8.41M | -$8.46M | -$15.58M | -$25.08M | -$29.25M | -$14.66M | -$3.37M | -$2.68M | |
| — | $63K | $59K | $65K | $28K | $45K | $4000 | $24K | — | $27K | $1000 | $4000 | $12K | $8000 | $2000 | $47K | $47K | |
| -$51.31M | -$48.79M | -$32.01M | -$19.92M | -$18.49M | -$14.92M | -$10.54M | -$10.04M | -$7.24M | -$8.44M | -$8.46M | -$15.59M | -$25.1M | -$29.26M | -$14.67M | -$3.42M | -$2.72M | |
| — | -543.33% | -456.63% | -320.97% | -357.59% | -331.88% | -424.31% | -269.82% | -201.06% | -305.61% | -446.73% | -674.68% | -890.53% | -600.41% | -244.25% | -69.1% | -79.86% | |
| — | — | — | — | — | — | — | — | -$7.7M | -$13.03M | -$8.46M | — | — | — | — | — | — | |
| USD/shares | — | -$0.76 | -$0.76 | -$0.82 | -$2.35 | -$2.03 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.76 | -$0.76 | -$0.82 | -$2.35 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 64.33M | 41.93M | 24.27M | 7.87M | 7.35M | 1.51M | 139.33K | 30.77K | 24.83K | 2715.4667 | 18.6K | 235.96K | 1.4M | — | — | — |
| shares | — | 64.33M | 41.93M | 24.27M | 7.87M | 7.35M | 1.51M | 139.33K | 30.77K | 24.83K | 2715.4667 | 18.6K | 235.96K | 1.4M | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2014: $42K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.19×
EV/EBIT
—
Medical Devices median 21.50×
P/E (TTM)
—
Medical Devices median 27.84×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Other Countries | $4,061,000 | $3,421,000 | $3,376,000 | $2,954,000 | $2,566,000 | $1,181,000 |
| United States | $1,417,000 | $32,000 | — | — | — | — |
| Germany | $1,233,000 | $926,000 | $896,000 | $866,000 | $948,000 | $708,000 |
| Italy | $1,232,000 | $1,223,000 | $1,195,000 | $970,000 | $981,000 | $596,000 |
| Poland | $1,036,000 | $694,000 | — | — | — | — |
| Russia | — | $713,000 | $738,000 | $381,000 | — | — |
By Product & Service (USD)
| Component | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| CGuard EPS | $6,205,000 | $5,123,000 | $4,309,000 | $2,764,000 |
| MGuard Prime EPS | — | $48,000 | $186,000 | -$279,000 |